Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21
Bryn M. Owen, David J. Mangelsdorf, Steven A. Kliewer
Trends in Endocrinology and Metabolism (2014) Vol. 26, Iss. 1, pp. 22-29
Open Access | Times Cited: 271

Showing 1-25 of 271 citing articles:

Targeting adipose tissue in the treatment of obesity-associated diabetes
Christine M. Kusminski, Perry E. Bickel, Philipp E. Scherer
Nature Reviews Drug Discovery (2016) Vol. 15, Iss. 9, pp. 639-660
Closed Access | Times Cited: 612
The Klotho proteins in health and disease
Makoto Kuro‐o
Nature Reviews Nephrology (2018) Vol. 15, Iss. 1, pp. 27-44
Closed Access | Times Cited: 558
New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond
Ulrich Beuers, Michael Trauner, Peter L. M. Jansen, et al.
Journal of Hepatology (2015) Vol. 62, Iss. 1, pp. S25-S37
Open Access | Times Cited: 466
A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects
Saswata Talukdar, Yingjiang Zhou, Dongmei Li, et al.
Cell Metabolism (2016) Vol. 23, Iss. 3, pp. 427-440
Open Access | Times Cited: 440
Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
Chiara Degirolamo, Carlo Sabbà, Antonio Moschetta
Nature Reviews Drug Discovery (2015) Vol. 15, Iss. 1, pp. 51-69
Closed Access | Times Cited: 381
Innate immunity in diabetes and diabetic nephropathy
Jun Wada, Hirofumi Makino
Nature Reviews Nephrology (2015) Vol. 12, Iss. 1, pp. 13-26
Closed Access | Times Cited: 367
Blaming the Brain for Obesity: Integration of Hedonic and Homeostatic Mechanisms
Hans‐Rudolf Berthoud, Heike Münzberg, Christopher D. Morrison
Gastroenterology (2017) Vol. 152, Iss. 7, pp. 1728-1738
Open Access | Times Cited: 362
Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease
Saurav Singh, Alexander Grabner, Christopher Yanucil, et al.
Kidney International (2016) Vol. 90, Iss. 5, pp. 985-996
Open Access | Times Cited: 320
FGF21 Regulates Sweet and Alcohol Preference
Saswata Talukdar, Bryn M. Owen, Parkyong Song, et al.
Cell Metabolism (2015) Vol. 23, Iss. 2, pp. 344-349
Open Access | Times Cited: 294
Signaling pathways in obesity: mechanisms and therapeutic interventions
Xue Wen, Bohan Zhang, Beiyi Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 244
Bile Acid Signaling Pathways from the Enterohepatic Circulation to the Central Nervous System
Kim L. Mertens, Andries Kalsbeek, Maarten R. Soeters, et al.
Frontiers in Neuroscience (2017) Vol. 11
Open Access | Times Cited: 240
KLB is associated with alcohol drinking, and its gene product β-Klotho is necessary for FGF21 regulation of alcohol preference
Günter Schumann, Chunyu Liu, Paul F. O’Reilly, et al.
Proceedings of the National Academy of Sciences (2016) Vol. 113, Iss. 50, pp. 14372-14377
Open Access | Times Cited: 230
FGF21 Lowers Plasma Triglycerides by Accelerating Lipoprotein Catabolism in White and Brown Adipose Tissues
Christian Schlein, Saswata Talukdar, Markus Heine, et al.
Cell Metabolism (2016) Vol. 23, Iss. 3, pp. 441-453
Open Access | Times Cited: 227
FGF19, FGF21, and an FGFR1/β-Klotho-Activating Antibody Act on the Nervous System to Regulate Body Weight and Glycemia
Tian Lan, Donald A. Morgan, Kamal Rahmouni, et al.
Cell Metabolism (2017) Vol. 26, Iss. 5, pp. 709-718.e3
Open Access | Times Cited: 217
Structures of β-klotho reveal a ‘zip code’-like mechanism for endocrine FGF signalling
Sangwon Lee, Jungyuen Choi, Jyotidarsini Mohanty, et al.
Nature (2018) Vol. 553, Iss. 7689, pp. 501-505
Open Access | Times Cited: 198
Citrus Flavonoids as Regulators of Lipoprotein Metabolism and Atherosclerosis
Erin E. Mulvihill, Amy C. Burke, Murray W. Huff
Annual Review of Nutrition (2016) Vol. 36, Iss. 1, pp. 275-299
Open Access | Times Cited: 196
Up to date on cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesis
John Y.L. Chiang, Jessica M. Ferrell
Liver Research (2020) Vol. 4, Iss. 2, pp. 47-63
Open Access | Times Cited: 187
Fibroblast growth factor 19 regulates skeletal muscle mass and ameliorates muscle wasting in mice
Bérengère Benoit, Emmanuelle Meugnier, Martina Castelli, et al.
Nature Medicine (2017) Vol. 23, Iss. 8, pp. 990-996
Open Access | Times Cited: 184
Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis
Lucas D. BonDurant, Matthew J. Potthoff
Annual Review of Nutrition (2018) Vol. 38, Iss. 1, pp. 173-196
Open Access | Times Cited: 176
Metabolic Responses to Dietary Protein Restriction Require an Increase in FGF21 that Is Delayed by the Absence of GCN2
Thomas Laeger, Diana C. Albarado, Susan J. Burke, et al.
Cell Reports (2016) Vol. 16, Iss. 3, pp. 707-716
Open Access | Times Cited: 173
Bile Acids and FXR: Novel Targets for Liver Diseases
Mary Stofan, Grace L. Guo
Frontiers in Medicine (2020) Vol. 7
Open Access | Times Cited: 153
Transferrin receptor 1 ablation in satellite cells impedes skeletal muscle regeneration through activation of ferroptosis
Hongrong Ding, Shujie Chen, Xiaohan Pan, et al.
Journal of Cachexia Sarcopenia and Muscle (2021) Vol. 12, Iss. 3, pp. 746-768
Open Access | Times Cited: 112
FXR in liver physiology: Multiple faces to regulate liver metabolism
Katrin Panzitt, Martin Wagner
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2021) Vol. 1867, Iss. 7, pp. 166133-166133
Open Access | Times Cited: 111
New developments in the biology of fibroblast growth factors
David M. Ornitz, Nobuyuki Itoh
WIREs Mechanisms of Disease (2022) Vol. 14, Iss. 4
Open Access | Times Cited: 96
Targeting the FGF19–FGFR4 pathway for cholestatic, metabolic, and cancerous diseases
Xiaokun Li, Weiqin Lu, Alexei Kharitonenkov, et al.
Journal of Internal Medicine (2024) Vol. 295, Iss. 3, pp. 292-312
Open Access | Times Cited: 24
Page 1 - Next Page

Scroll to top